Blockchain Registration Transaction Record
GeoVax Highlights Need for Domestic Vaccine Manufacturing Amid Global Outbreaks
GeoVax stresses importance of scalable U.S.-based vaccine manufacturing amid WHO Ebola emergency and mpox spread. GEO-MVA mpox/smallpox vaccine advances with Phase 3 trial planned for 2026.
This news matters because it underscores the fragility of global vaccine supply chains and the critical need for diversified, scalable domestic manufacturing to respond swiftly to emerging infectious disease threats. As the WHO declares emergencies for Ebola and mpox, the advancement of GEO-MVA and similar platforms could be pivotal in ensuring long-term biodefense readiness and protecting public health against future pandemics.
| Blockchain | Details |
|---|---|
| Contract Address | 0xeA2912a8DA1CD48401b10cB283585874d98098F4 |
| Transaction ID | 0x7ed9ba3e8e4a23de78a2a5d9cba57470d7b9822bcc0daeb63575146fac9c94d7 |
| Account | 0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20 |
| Chain | polygon-main |
| NewsRamp Digital Fingerprint | blurhax7-3182790540b348dcfe221d2915ff8943 |